164 related articles for article (PubMed ID: 34187410)
1. Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels.
Huang J; Hu M; Niu H; Wang J; Si Y; Cheng S; Ding W
BMC Cancer; 2021 Jun; 21(1):750. PubMed ID: 34187410
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of osteopontin splicing isoform c defines its role as a microenvironmental factor to promote the survival of colon cancer cells from 5-FU treatment.
Chang S; Huang J; Niu H; Wang J; Si Y; Bai Z; Cheng S; Ding W
Cancer Cell Int; 2020; 20():452. PubMed ID: 32944000
[TBL] [Abstract][Full Text] [Related]
3. Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer.
Goparaju CM; Pass HI; Blasberg JD; Hirsch N; Donington JS
J Thorac Oncol; 2010 Oct; 5(10):1516-23. PubMed ID: 20689445
[TBL] [Abstract][Full Text] [Related]
4. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells.
Tilli TM; Mello KD; Ferreira LB; Matos AR; Accioly MT; Faria PA; Bellahcène A; Castronovo V; Gimba ER
Prostate; 2012 Nov; 72(15):1688-99. PubMed ID: 22495819
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin-c splicing isoform contributes to ovarian cancer progression.
Tilli TM; Franco VF; Robbs BK; Wanderley JL; da Silva FR; de Mello KD; Viola JP; Weber GF; Gimba ER
Mol Cancer Res; 2011 Mar; 9(3):280-93. PubMed ID: 21263033
[TBL] [Abstract][Full Text] [Related]
6. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.
Wu J; Pungaliya P; Kraynov E; Bates B
Biomarkers; 2012 Mar; 17(2):125-33. PubMed ID: 22188260
[TBL] [Abstract][Full Text] [Related]
7. Distinctive Prognostic Value and Cellular Functions of Osteopontin Splice Variants in Human Gastric Cancer.
Hao C; Cui Y; Lane J; Jia S; Ji J; Jiang WG
Cells; 2021 Jul; 10(7):. PubMed ID: 34359989
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
[TBL] [Abstract][Full Text] [Related]
9. Osteopontin is a prognostic biomarker in non-small cell lung cancer.
Rud AK; Boye K; Oijordsbakken M; Lund-Iversen M; Halvorsen AR; Solberg SK; Berge G; Helland A; Brustugun OT; Mælandsmo GM
BMC Cancer; 2013 Nov; 13():540. PubMed ID: 24215488
[TBL] [Abstract][Full Text] [Related]
10. NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ALDH axis in lung adenocarcinoma.
Xiao ZJ; Liu J; Wang SQ; Zhu Y; Gao XY; Tin VP; Qin J; Wang JW; Wong MP
Elife; 2017 Jul; 6():. PubMed ID: 28737489
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin isoforms differentially promote arteriogenesis in response to ischemia via macrophage accumulation and survival.
Lee GS; Salazar HF; Joseph G; Lok ZSY; Caroti CM; Weiss D; Taylor WR; Lyle AN
Lab Invest; 2019 Mar; 99(3):331-345. PubMed ID: 29959420
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.
Nakamura KD; Tilli TM; Wanderley JL; Palumbo A; Mattos RM; Ferreira AC; Klumb CE; Nasciutti LE; Gimba ER
Tumour Biol; 2016 Feb; 37(2):2655-63. PubMed ID: 26404131
[TBL] [Abstract][Full Text] [Related]
13. Enhanced osteopontin splicing regulated by RUNX2 is HDAC-dependent and induces invasive phenotypes in NSCLC cells.
Huang J; Chang S; Lu Y; Wang J; Si Y; Zhang L; Cheng S; Jiang WG
Cancer Cell Int; 2019; 19():306. PubMed ID: 31832019
[TBL] [Abstract][Full Text] [Related]
14. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways.
Courter D; Cao H; Kwok S; Kong C; Banh A; Kuo P; Bouley DM; Vice C; Brustugun OT; Denko NC; Koong AC; Giaccia A; Le QT
PLoS One; 2010 Mar; 5(3):e9633. PubMed ID: 20224789
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer.
Gu T; Ohashi R; Cui R; Tajima K; Yoshioka M; Iwakami S; Sasaki S; Shinohara A; Matsukawa T; Kobayashi J; Inaba Y; Takahashi K
Lung Cancer; 2009 Nov; 66(2):176-83. PubMed ID: 19285749
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin b and c Splice isoforms in Leukemias and Solid Tumors: Angiogenesis Alongside Chemoresistance.
Mirzaei A; Mohammadi S; Ghaffari SH; Yaghmaie M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Asian Pac J Cancer Prev; 2018 Mar; 19(3):615-623. PubMed ID: 29580029
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of osteopontin, αvβ3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer.
Jin Y; Tong DY; Chen JN; Feng ZY; Yang JY; Shao CK; Li JP
PLoS One; 2012; 7(10):e48575. PubMed ID: 23119061
[TBL] [Abstract][Full Text] [Related]
18. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin expression is associated with platinum-based chemotherapy response and prognosis of patients with advanced non small cell lung cancer.
Zhang T; Zhang DM; Zhao D; Hou XM; Yang TN
J BUON; 2014; 19(3):742-8. PubMed ID: 25261661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
